Objective To observe the application of venecra combined with demethylation drugs in patients with acute myeloid leukemia(AML)unfavorable for standard chemotherapy.Methods A total of 80 patients with AML who were hospitalized in the Fifth People's Hospital of Datong from January 2020 to December 2023 were prospectively selected as the research objects.After evaluation before treatment,all patients were not suitable for standard chemotherapy.According to the envelope method,they were divided into the control group and the study group,with 40 cases in each group.The control group received cytarabine monotherapy,and the study group received venecra combined with normethyl drug(cytarabine single agent).The therapeutic effects of the two groups were compared.The hemogram indexes(white blood cell count,hemoglobin,platelet count)and lymphocyte subsets of the two groups were recorded before and after 4 cycles of treatment.The adverse reactions of the two groups during the treatment were recorded.The patients were followed up for 2 years,and the survival of the two groups was recorded.Results The effective rate of treatment in the study group was 82.50％,which was higher than that in the control group(50.00％),and the difference was statistically significant(P＜0.05).After 4 cycles of treatment,the white blood cell count of the two groups were lower than those before treat-ment,and the hemoglobin and platelet count were higher than those before treatment.The white blood cell count of the study group was(7.12±1.45)× 109/L,which was lower than that of the control group[(8.23±1.87)×109/L],the hemoglobin and platelet count were(135.50±2.00)g/L and(114.96±1.23)× 109/L,which were higher than those of the control group[(122.00±1.50)g/L,(106.68±1.74)× 109/L],the differences were statistically significant(P＜0.05).After 4 cycles of treatment,the levels of CD3+and CD4+in the two groups were higher than those before treatment,and the levels of CD8+were lower than those before treatment,the levels of CD3+and CD4+in the study group were(64.55±3.18)％and(45.58±2.46)％,respectively,which were higher than those in the control group[(57.36±3.12)％,(37.45±2.15)％],and the level of CD8+was(22.38±1.02)％,which was lower than that in the control group[(25.49±1.38)％],the differences were statistically significant(P＜0.05).There were no statistically significant differences in non-hematological adverse reactions and hematological adverse reactions between the two groups(P＞0.05).The average survival time and median survival time of the study group were higher than those of the control group,and the differences were statistically significant(P＜0.05).Conclusion Vinecra combined with demethylation drugs can improve treatment efficiency in AML patients,improve hemogram indicators and lymphocyte subset levels,and help to im-prove the survival time of patients,without significantly elevating the risk of adverse reactions,which is an effective treatment option.
维普
万方数据